Capable of structural modulation, this nanoswitch is even applicable to proteins with unknown functions. capacity to form stable linkages with target molecules. A significant focus is placed on proximity-enabled reactive therapeutics (PERx), a pioneering technology in covalent protein therapeutics. We detail its wide-ranging applications in immunotherapy, viral neutralization, and targeted radionuclide therapy. Finally, we present a perspective on the existing challenges within biospecific chemistry and discuss the potential avenues for future exploration and advancement in this rapidly evolving field. 1.?Introduction There exist four major classes of biomacromolecules in life forms on earth: proteins, nucleic acids, carbohydrates, and lipids. These biomacromolecules engage in intricate interactions, collaborating to execute diverse biological functions essential for life. Their interactions, which encompass electrostatic forces, van der Waals forces, -effects, and hydrophobic effects, are primarily noncovalent in nature. Covalent connections between biomacromolecules usually require enzymatic catalysis, such as the attachment of ubiquitin and ubiquitin-like proteins to other proteins,1 as well as the attachment of glycans to proteins, lipids, and RNAs.2 Interaction through spontaneous covalent bonding is rare, with Gusperimus trihydrochloride the formation of disulfide bonds in proteins between cysteine residues being a notable exception.3 Although other covalent bonds, such as the isopeptide bond and NCOCS bridge, have been identified in certain proteins,4,5 their formation demands a specialized protein microenvironment, limiting their general applicability across diverse proteins. Noncovalent interactions are typically characterized by their relative weakness, transience, and reversibility. In contrast, covalent bonding offers a more robust, selective, and stable form of connection. Although evolutionary pressure has not favored the proliferation of additional covalent linkages in biomolecules, exploring new covalent bonds holds the potential to unlock novel structures, properties, and functions.6 This exploration is particularly valuable for advancing the research, control, and utilization of biological activities. For covalent reactions with biomacromolecules, bio-orthogonal click chemistry has gained prominence.7,8 These reactions avoid interference with biological processes and efficiently occur under physiological conditions between two abiotic bio-orthogonal functional groups. One bio-orthogonal functional group is introduced into target biomolecules through Gusperimus trihydrochloride metabolic or genetic engineering, while the complementary group is integrated into the probe molecule.9 This setup allows for the selective formation of covalent bonds between the probe and the target biomolecule in the presence of other biomolecules. While bio-orthogonal click chemistry has transformed chemical biology and significantly advanced biotechnology, its application in living organisms may be hindered by the impracticality of introducing exogenous components in certain situations, particularly for in vivo applications involving disease-related biomacromolecules in humans. Over the past decade, biospecific chemistry has flourished, enabling the selective covalent targeting of endogenous biomacromolecules in cells and organisms without altering the target biomacromolecules themselves. This approach requires only one latent bioreactive functional group in the reactant biomacromolecule, which selectively reacts with the target biomacromolecule upon binding.6,10,11 Unlike bio-orthogonal chemistry, which is designed not to react with endogenous biomacromolecules, biospecific LEG2 antibody chemistry is tailored to react with native biomacromolecules under cellular or physiological conditions with high specificity. While bio-orthogonal chemistry has primarily been used for labeling biomacromolecules with small-molecule probes, biospecific chemistry aims to create covalent linkages within or between biomacromolecules. Here, we provide an account of the development of biospecific chemistry, tracing its initiation in proteins. We discuss the design and introduction of different latent bioreactive functional groups into proteins to covalently target various amino acid residues of Gusperimus trihydrochloride proteins, ribonucleic acids, and carbohydrates. Additionally, we showcase how these new covalent linkages among biomacromolecules facilitate the engineering of challenging protein properties, enable the capture of elusive biomolecular interactions in situ for subsequent identification, and support the development of peptide and protein therapeutics that operate in a covalent mode. We conclude with a discussion of the future development of biospecific chemistry and directions to be explored. 2.?Biospecific Chemistry to Target Different Classes of Biomacromolecules The foundational methodology of biospecific chemistry involves the integration of a latent bioreactive functional group into biomolecule A that is designed to selectively target a specific natural functional group in biomolecule B (Figure ?Figure11). The interaction between biomolecules A and B brings the latent bioreactive group into close proximity with its target natural group. Such proximity leads to an increased effective concentration and a reduction in entropy loss, thereby activating the latent bioreactive groups reaction toward its target group and resulting in the formation of a precise covalent bond. We refer to this process as biospecific chemistry, which enables the specific covalent targeting of biomolecules without requiring modifications to Gusperimus trihydrochloride the target molecules themselves. Furthermore, biomolecules A and B may belong to different classes; the reaction is also viable within a single biomacromolecule and is applicable across diverse environments, including in vitro conditions, live cells, and whole organisms..